Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06834035
PHASE1/PHASE2

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Sponsor: M. Peter Marinkovich

View on ClinicalTrials.gov

Summary

The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.

Key Details

Gender

All

Age Range

6 Years - Any

Study Type

INTERVENTIONAL

Enrollment

8

Start Date

2025-08-04

Completion Date

2027-03

Last Updated

2026-03-25

Healthy Volunteers

No

Interventions

BIOLOGICAL

Immunoglobulin G

Purified IgG from human serum, delivered via IV

Locations (1)

Stanford University

Redwood City, California, United States